Impact of Remote Vital Signs Monitoring in People Using Long-term Oxygen Therapy

Who May Qualify: - Patients with a clinical, radiological and/or anatomopathological diagnosis of COPD and ILD according to the 2020 ATS/JRS/ALAT guidelines; - Age over 18 years; - Clinical stability (absence of exacerbations or hospitalizations related to the underlying disease) for at least 6 weeks; - Patients who are on optimized drug therapy, including long-term home oxygen therapy (LTOT) - Have a smartphone compatible with the monitoring device; - Signing of the ICF to participate in the study. Who Should NOT Join This Trial: - Presence of other concomitant lung diseases; - Myocardial infarction within four months prior to the start of the study, unstable angina or severe heart disease (NYHA functional class III-IV) and/or decompensated. - Patients who received a lung transplant during the study - Living outside the coverage area or moving out of state Always talk to your doctor about whether this trial is right for you.